-
Genzyme drug shows improvement in MS patients
CAMBRIDGE, Mass. — Disease relapse rates and worsening of disability were low among patients taking a drug made by Genzyme for multiple sclerosis, the company said.
Genzyme, a division of French drug maker Sanofi, announced results of an extension study of the drug Lemtrada (alemtuzumab). The study was a follow-up to two other late-stage clinical studies of the drug, finding that relapse rates and sustained accumulation of disability remained low among patients who had previously received the drug.
-
Study finds improvements in cardiovascular health among South Asians who receive culturally relevant coaching
MOUNTAIN VIEW, Calif. — Culturally competent coaching may be effective in reducing the risk of coronary artery disease among South Asian patients, according to a new study presented as a poster at an American Heart Association conference taking place in New Orleans.